Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EsPhALL2017/COGAALL1631 trial in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia
NL-OMON59543Phase 3Active, not recruiting
- Sponsor
- University of Milano-Bicocca
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imatinib in acute lymphoblastic leukemia (ALL) and mixed phenotype acute leukemia (MPAL) (2 arms), sponsored by University of Milano-Bicocca. Primary endpoint: Disease-free survival. Started Jul 2018; status: active, not recruiting.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NL-OMON59543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59543.